association

Full identifier: http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#association

Searching for classes... Loading...

Searching for instances... Loading...

Searching for templates... Loading...

Minted in Nanopublication

 RAVco7IKl4 comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAVco7IKl4...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 1 1 mm as maintenance following autologous hematopoietic stem cell transplantation auto hsct 1 1 transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 1 2 mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 1 3 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 1 4 revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mm revlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation auto hsct revlimid is indicated for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib revlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 5 5" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVco7IKl4... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T12:50:52.635+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVco7IKl4... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVco7IKl4... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAVco7IKl4... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAVco7IKl4...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAVco7IKl4... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAVco7IKl4...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 10:50:52 UTC

References

Loading...

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)